Why Is There No Generic Insulin? Historical Origins of a Modern Problem

Jeremy A. Greene · Kevin R. Riggs

81 citations0/0 files storedNew England Journal of Medicine

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Pharmaceutical Economics and Policy Healthcare Policy and Management Biosimilars and Bioanalytical Methods

Abstract

Six million U.S. patients with diabetes take insulin, which was discovered in 1921 — yet is available only in brand-name forms. The reasons why an agent discovered almost 100 years ago is still unavailable as a low-priced generic have implications for policy and practice.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 81 citations exist upstream.

References

2001Adverse Events Associated With Prescription Drug Cost-Sharing Among Poor and Elderly Persons 2013Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia 2004Problems Paying Out-of-Pocket Medication Costs Among Older Adults With Diabetes 2005Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997–2000 2011Demythologizing the high costs of pharmaceutical research 1996Longer Patents for Increased Generic Competition in the US 2007The Ongoing Regulation of Generic Drugs 2008‘Patenting in the public interest:’ administration of insulin patents by the University of Toronto

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.